Advertisement

Clinical and Translational Oncology

, Volume 15, Issue 5, pp 358–363 | Cite as

Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx

  • F. Mera-Menéndez
  • A. Hinojar-Gutiérrez
  • M. Guijarro Rojas
  • J. García de Gregorio
  • E. Mera-Menéndez
  • J. J. Sánchez
  • M. Quintanilla
  • L. Cerezo
  • C. Gamallo
Educational Series - Blue Series ADVANCES IN TRANSLATIONAL ONCOLOGY

Abstract

Background

HIF-1alpha plays a key role in the development and progression of cancer. Its polymorphic variants C1772T and G1790A have been associated with greater susceptibility to cancer and increased tumor progression.

Methods

We determined the distribution of these polymorphisms among 121 patients with glottic cancer and 154 healthy volunteers by PCR–RFLP. We also analyzed the relationship between the presence of these polymorphisms and various clinicopathologic variables.

Results

Advanced tumors (T3–T4) were associated with the TT variant (p = 0.036), which was present in 75 % of T4 tumors (p = 0.008).

Among patients with nodal metastasis (N+), 41.7 and 22 % were carrying the TT and GA variants, respectively, compared with 9.4 and 2 % of the patients with no metastasis (N0), (p = 0.006 and p = 0.032).

Conclusions

The presence of the TT and GA variants were associated with lymph node metastasis, while the presence of the TT variant can be associated with larger tumor size.

Keywords

HIF-1 HIF-1alpha Polymorphism Glottic cancer Laryngeal cancer 

Notes

Acknowledgments

We thank Thomas O’Boyle for editorial assistance and Yolanda Suárez Del Val for her help with the molecular analysis. This work was supported by the Foundation for Biomedical Research, Hospital Universitario de La Princesa.

Supplementary material

12094_2012_930_MOESM1_ESM.doc (322 kb)
Supplementary material 1 (DOC 321 kb)
12094_2012_930_MOESM2_ESM.doc (78 kb)
Supplementary material 2 (DOC 78 kb)

References

  1. 1.
    Parkin DM, Whelan SL, Ferlay J, Storm H (2005) Cancer incidence in five continents: vol. I, to VIII. IARC Cancer Base, No 7, LyonGoogle Scholar
  2. 2.
    Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M (2005) Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur J Cancer 41:683–693PubMedCrossRefGoogle Scholar
  3. 3.
    Bartsch H, Dally H, Popanda O, Risch A, Schmezer P (2007) Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res 174:19–36PubMedCrossRefGoogle Scholar
  4. 4.
    Vaupel P, Mayer A, Höckel M (2004) Tumor hypoxia and malignant progression. Methods Enzymol 381:335–354PubMedCrossRefGoogle Scholar
  5. 5.
    Acker T, Plate KH (2002) A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J Mol Med 80:562–575PubMedCrossRefGoogle Scholar
  6. 6.
    Hirota K, Semenza G (2006) Regulation of angiogénesis by hypoxia-inducible factor I. Crit Rev Oncol Hematol 59:15–26PubMedCrossRefGoogle Scholar
  7. 7.
    Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K (2003) Hypoxia-inducible factor-1 alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24:1779–1783PubMedCrossRefGoogle Scholar
  8. 8.
    Secades P, Rodrigo J, Hermsen M, Alvarez C, Suarez C, Chiara MD (2009) Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas. Genes Chromosom Cancer 48:441–454PubMedCrossRefGoogle Scholar
  9. 9.
    Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER (2001) The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 20:5067–5074PubMedCrossRefGoogle Scholar
  10. 10.
    Zhao T, Lv J, Zhao J, Nzekebaloudou M (2009) Hypoxia inducible factor-1 alpha gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res 28:159PubMedCrossRefGoogle Scholar
  11. 11.
    Cancer, American Join Committee on Cancer/International Union Against. American Join Committee on Cancer (2002) 6th Edition. http://www.cancerstaging.org/
  12. 12.
    Warren S, Gates O (1932) Multiple malignant tumors: a survey of literature and statistical study. Am J Cancer 51:1358–1414Google Scholar
  13. 13.
    Fransén K, Fenech M, Fredrikson M, Dabrosin C, Söderkvist P (2006) Association between ulcerative growth and hypoxia inducible factor-1 alpha polymorphisms in colorectal cancer patients. Mol Carcinog 45:833–840PubMedCrossRefGoogle Scholar
  14. 14.
    Hardy GH (1908) Mendelian proportions in a mixed population. Science 28:49–50PubMedCrossRefGoogle Scholar
  15. 15.
    Weinberg W (1908) Über den Nachweis der Vererbung beim Menschen. Jahreshefle des Vereins für vaterländische Naturkunde in Württemberg 64:368–382Google Scholar
  16. 16.
    HapMap Project (2007) CEPH population. http://www.ncbi.nih.gov/SNP/snp_ref.cgi?rs=11549465
  17. 17.
    HapMap Project (2007) CEPH population. http://www.ncbi.nih.gov/SNP/snp_ref.cgi?rs=11549467
  18. 18.
    Bartsch H, Hietanen E (1996) The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 104:569–577PubMedGoogle Scholar
  19. 19.
    Abbasi R, Ramroth H, Becher H, Dietz A, Schmezer P, Popanda O (2009) Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERC6 and RAD23B but not polymorphisms in five other nucleotide excision repair genes. Int J Cancer 125:1431–1439PubMedCrossRefGoogle Scholar
  20. 20.
    Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population based assessment of cancer risk in first-degree relative of cancer probands. J Natl Cancer Inst 86:1600–1608PubMedCrossRefGoogle Scholar
  21. 21.
    Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA (1996) Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 313:716–721PubMedCrossRefGoogle Scholar
  22. 22.
    Cui Y, Morgenstern H, Greenland S et al (2006) Polymorphism of xeroderma pigmentosum group G and the risk of lung cancer and squamous cell carcinoma of the oropharynx, larynx and esophagus. Int J Cancer 118:714–720PubMedCrossRefGoogle Scholar
  23. 23.
    Sturgis EM, Wei Q (2002) Genetic susceptibility-molecular epidemiology of head and neck cancer. Curr Opin Oncol 14:310–317PubMedCrossRefGoogle Scholar
  24. 24.
    Katsuta M, Miyashita M, Makino H et al (2005) Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 78:123–130PubMedCrossRefGoogle Scholar
  25. 25.
    Batmunkh E, Shimada M, Morine Y et al (2010) Expression of hypoxia inducible factor -1 alpha (HIF-1alpha) in patients with gallbladder carcinoma. Int J Clin Oncol 15:59–64PubMedCrossRefGoogle Scholar
  26. 26.
    Aebersold DM, Burri P, Beer KT et al (2001) Expression of hypoxia inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911–2916PubMedGoogle Scholar
  27. 27.
    Lin PY, Yu CH, Wang JT, Chiang CP et al (2008) Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 37:18–25PubMedCrossRefGoogle Scholar
  28. 28.
    Muñoz-Guerra MF, Fernández-Contreras ME, Moreno AL, Martín ID, Herráez B, Gamallo C (2009) Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol 16:2351–2358PubMedCrossRefGoogle Scholar
  29. 29.
    Chen MK, Chiou H, Su SC et al (2009) The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. Oral Oncol 45:222–226CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  • F. Mera-Menéndez
    • 1
  • A. Hinojar-Gutiérrez
    • 1
  • M. Guijarro Rojas
    • 2
  • J. García de Gregorio
    • 1
  • E. Mera-Menéndez
    • 3
  • J. J. Sánchez
    • 4
  • M. Quintanilla
    • 5
  • L. Cerezo
    • 6
  • C. Gamallo
    • 2
    • 7
  1. 1.Departamento de Otorrinolaringología, Hospital Universitario de La PrincesaUniversidad Autónoma de MadridMadridSpain
  2. 2.Departamento de Anatomía Patológica, Hospital Universitario de La PrincesaUniversidad Autónoma de MadridMadridSpain
  3. 3.Departamento de Sistemas Informáticos y ComputaciónUniversidad Complutense de MadridMadridSpain
  4. 4.Departamento de Medicina PreventivaFacultad de Medicina, Universidad Autónoma de MadridMadridSpain
  5. 5.Instituto de investigaciones Biomédicas “Alberto Sols”, CSIC-UAMUniversidad Autónoma de MadridMadridSpain
  6. 6.Departamento de Oncología Radioterápica, Hospital Universitario de la PrincesaUniversidad Autónoma de MadridMadridSpain
  7. 7.Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED)BarcelonaSpain

Personalised recommendations